SCHEMBL1706233

SCHEMBL1706233

COC(=O)c1coc(Cc2cccc(C(C)=O)c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.44
DAGLA Q9Y4D2 1/20 0.43
CYP4F2 P78329 2/20 0.43
CYP4A11 Q02928 2/20 0.43
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
SLC7A5 Q01650 1/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 1/20 0.41
KLKB1 P03952 2/20 0.41
IL4I1 Q96RQ9 1/20 0.40
MPO P05164 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPK1 P28482 1/20 0.40
MAOB P27338 1/20 0.39
ABHD6 Q9BV23 1/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1707161 0.86 LMNA (0.43) DAGLALMNAMAPTKLKB1IL4I1
SCHEMBL1706806 0.85 IL4I1 (0.42) LMNAMAPTKLKB1IL4I1SMN1; SMN2
SCHEMBL11910637 0.83 DAGLA (0.55) DAGLASLC6A2SLC6A4SLC6A3LMNA
SCHEMBL1705881 0.80 DAGLA (0.39) DAGLASLC6A2SLC6A4SLC6A3KLKB1
SCHEMBL27899551 0.79 IL4I1 (0.38) DAGLALMNAMAPTKLKB1IL4I1
SCHEMBL28802129 0.78 LMNA (0.43) SLC7A5LMNAMAPTKLKB1IL4I1
SCHEMBL1975554 0.76 KLKB1 (0.56) DAGLASLC6A2SLC6A4SLC6A3LMNA
SCHEMBL1706746 0.75 LMNA (0.40) SLC7A5LMNAMAPTIL4I1SMN1; SMN2
SCHEMBL27899559 0.75 LMNA (0.38) LMNAMAPTIL4I1MAPK1MAOB
SCHEMBL5219307 0.74 SLC6A2 (0.42) DAGLASLC6A2SLC6A4SLC6A3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102803237-B Oxazole and thiazole derivatives as alx receptor agonists ACTELION PHARMACEUTICALS LTD 2014-09-24 CN disclosed
US-8674111-B2 Oxazole and thiazole derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD. (CH) 2014-03-18 US disclosed
EP-2440536-B1 Oxazole and thiazole derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD (CH) 2013-11-06 EP disclosed
CN-102803237-A Oxazole and thiazole derivatives as alx receptor agonists ACTELION PHARMACEUTICALS LTD 2012-11-28 CN disclosed
US-20120115916-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2012-05-10 US disclosed
EP-2440536-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2012-04-18 EP disclosed
WO-2010143158-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115916-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS P2RX1, GLP1R, P2RX7 LOXL2 786/4885DAGLA 3893/4885CYP4F2 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.